Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Environ Health Perspect ; 132(2): 27012, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38415615

RESUMO

BACKGROUND: Endometrial cancer is a hormone-dependent cancer, and estrogens play a relevant role in its etiology. However, little is known about the effects of environmental pollutants that act as xenoestrogens or that influence estrogenic activity through different pathways. OBJECTIVE: We aimed to assess the relationship between the combined estrogenic activity of mixtures of xenoestrogens present in serum samples and the risk of endometrial cancer in the Screenwide case-control study. METHODS: The total effective xenoestrogen burden (TEXB) attributable to organohalogenated compounds (TEXB-α) and to endogenous hormones and more polar xenoestrogens (TEXB-ß) was assessed in serum from 156 patients with endometrial cancer (cases) and 150 controls by combining chemical extraction and separation by high-performance liquid chromatography with the E-SCREEN bioassay for estrogenicity. RESULTS: Median TEXB-α and TEXB-ß levels for cases (0.30 and 1.25 Eeq pM/mL, respectively) and controls (0.42 and 1.28 Eeq pM/mL, respectively) did not significantly differ (p=0.653 and 0.933, respectively). An inverted-U risk trend across serum TEXB-α and TEXB-ß levels was observed in multivariate adjusted models: Positive associations were observed for the second category of exposure in comparison to the lowest category of exposure [odds ratio (OR)=2.11 (95% CI: 1.13, 3.94) for TEXB-α, and OR=3.32 (95% CI: 1.62, 6.81) for TEXB-ß], whereas no significant associations were observed between the third category of exposure and the first [OR=1.22 (95% CI: 0.64, 2.31) for TEXB-α, and OR=1.58 (95% CI: 0.75, 3.33) for TEXB-ß]. In mutually adjusted models for TEXB-α and TEXB-ß levels, the association of TEXB-α with endometrial cancer risk was attenuated [OR=1.45 (95% CI: 0.61, 3.47) for the second category of exposure], as well as estimates for TEXB-ß (OR=2.68; 95% CI: 1.03, 6.99). Most of the individual halogenated contaminants showed no associations with both TEXB and endometrial cancer. CONCLUSIONS: We evaluated serum total xenoestrogen burden in relation to endometrial cancer risk and found an inverted-U risk trend across increasing categories of exposure. The use of in vitro bioassays with human samples may lead to a paradigm shift in the way we understand the negative impact of chemical mixtures on human health effects. These results are relevant from a public health perspective and for decision-makers in charge of controlling the production and distribution of chemicals with xenoestrogenic activity. https://doi.org/10.1289/EHP13202.


Assuntos
Neoplasias do Endométrio , Poluentes Ambientais , Feminino , Humanos , Estudos de Casos e Controles , Estrogênios/metabolismo , Poluentes Ambientais/metabolismo , Neoplasias do Endométrio/epidemiologia
2.
Cancer Epidemiol Biomarkers Prev ; 33(6): 788-795, 2024 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-38530242

RESUMO

BACKGROUND: The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors. METHODS: We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors. RESULTS: Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09-1.19). There was significant heterogeneity by study design (Phet < 0.01), with a stronger magnitude of association observed among case-control versus cohort studies. Stronger associations were also noted for pre-/perimenopausal women and never users of postmenopausal hormone therapy. CONCLUSIONS: Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. IMPACT: This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.


Assuntos
Neoplasias do Endométrio , Hipertensão , Humanos , Feminino , Neoplasias do Endométrio/epidemiologia , Fatores de Risco , Hipertensão/epidemiologia , Pessoa de Meia-Idade , Estudos de Casos e Controles , Idoso , Adulto , Incidência
3.
Dermatol. argent ; 18(1): 18-29, ene.-feb. 2012. tab, ilus
Artigo em Espanhol | LILACS | ID: lil-724291

RESUMO

Los inhibidores del receptor de factor de crecimiento epidérmico son un grupo de drogas nuevas usadas para el tratamiento de tumores en estadios avanzados. Estas drogas producen conmucha frecuencia toxicidad cutánea. El objetivo de este artículo es realizar una revisión de estas reacciones cutáneas y el manejo de las mismas.


Epidermal growth factor - receptor inhibitors constitute a new group of drugs used for the treatment of malignant tumors in advanced stages. These drugs produce with high frequency cutaneous toxicity. The aim of this paper is to review those cutaneous reactions, and their management.


Assuntos
Humanos , Receptores ErbB/antagonistas & inibidores , Antineoplásicos/efeitos adversos , Erupções Acneiformes/etiologia , Toxidermias/etiologia , Pele/patologia
4.
Dermatol. argent ; 18(1): 18-29, ene.-feb. 2012. tab, ilus
Artigo em Espanhol | BINACIS | ID: bin-128066

RESUMO

Los inhibidores del receptor de factor de crecimiento epidérmico son un grupo de drogas nuevas usadas para el tratamiento de tumores en estadios avanzados. Estas drogas producen conmucha frecuencia toxicidad cutánea. El objetivo de este artículo es realizar una revisión de estas reacciones cutáneas y el manejo de las mismas. (AU)


Epidermal growth factor - receptor inhibitors constitute a new group of drugs used for the treatment of malignant tumors in advanced stages. These drugs produce with high frequency cutaneous toxicity. The aim of this paper is to review those cutaneous reactions, and their management. (AU)


Assuntos
Humanos , Receptores ErbB/antagonistas & inibidores , Toxidermias/etiologia , Erupções Acneiformes/etiologia , Antineoplásicos/efeitos adversos , Pele/patologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa